Price
CHART BY
Frequently asked questions
What is 10X Genomics's market capitalization?
The market capitalization of 10X Genomics is $1.70B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for 10X Genomics?
10X Genomics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.527. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for 10X Genomics's stock?
Currently, 20 analysts cover 10X Genomics's stock, with a consensus target price of $20.20. Analyst ratings provide insights into the stock's expected performance.
What is 10X Genomics's revenue over the trailing twelve months?
Over the trailing twelve months, 10X Genomics reported a revenue of $629.74M.
What is the EBITDA for 10X Genomics?
10X Genomics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$133.38M. EBITDA measures the company's overall financial performance.
What is the free cash flow of 10X Genomics?
10X Genomics has a free cash flow of $26.04M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does 10X Genomics have, and what sector and industry does it belong to?
10X Genomics employs approximately 1,259 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of 10X Genomics's shares?
The free float of 10X Genomics is 99.75M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.70B
- EPS (TTM)
- -$1.527
- Free Float
- 99.75M
- Revenue (TTM)
- $629.74M
- EBITDA (TTM)
- -$133.38M
- Free Cashflow (TTM)
- $26.04M
Pricing
- 1D span
- $13.31$14.45
- 52W span
- $12.95$57.70
Analyst Ratings
The price target is $20.20 and the stock is covered by 20 analysts.
Buy
9
Hold
10
Sell
1
Information
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
- Employees
- 1,259
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US88025U1097
- Primary Ticker
- TXG